Therefore, blockade of EGFR signaling by either small-molecule inhibitors or anti-EGFR monoclonal antibodies may not only inhibit tumor growth but also exacerbate cachexia symptoms in clinical settings. The gene discussed is EGFR; the disease is neoplasm.